Shortwave Life Sciences (AQSE:PSY) Capital Expenditure : £0.00 Mil (TTM As of . 20)

View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Shortwave Life Sciences's cash flow for capital expenditures for the six months ended in . 20 was £0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in . 20 was £0.00 Mil.

Shortwave Life Sciences Capital Expenditure Historical Data

The historical data trend for Shortwave Life Sciences's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Capital Expenditure Chart

Shortwave Life Sciences Annual Data

Trend

Capital Expenditure

Shortwave Life Sciences Semi-Annual Data

Capital Expenditure

Shortwave Life Sciences Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Capital Expenditure for the trailing twelve months (TTM) ended in . 20 was £0.00 Mil.

Shortwave Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.shortwavelifesciences.com

Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.